BioCentury | Oct 11, 2017
Company News

Management tracks: Aerpio, Scancell, TCR2

...company Azitra Inc. (Farmington, Conn.) named Richard Andrews president and CEO. He was CEO of Thrasos Therapeutics Inc....
BioCentury | Mar 21, 2016
Clinical News

THR-184: Phase II data

...placebo or 1 of 4 dose levels of THR-184 administered prior to and after surgery. Thrasos Therapeutics Inc....
BioCentury | Jul 27, 2015
Clinical News

THR-184: Completed Phase II enrollment

...2 lower dose arms (see BioCentury, Oct. 6, 2014). Data are expected by January 2016. Thrasos Therapeutics Inc....
BioCentury | Apr 6, 2015
Financial News

Thrasos Therapeutics completes venture financing

Thrasos Therapeutics Inc. , Montreal, Quebec Business: Renal, Cancer, Musculoskeletal Date completed: 2015-03-31 Type: Venture financing Raised: $21 million Investors: BDC Capital; SROne; Fonds de solidarite FTQ; Lumira Capital; Advanced Technology Ventures; MP Healthcare Venture Management...
BioCentury | Apr 1, 2015
Financial News

Thrasos raises $21M in series D

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $21 million in a series D round led by new investor BDC Capital and existing investor SR One. Current investors Advanced Technology Ventures; Fonds de solidarite FTQ; Lumira Capital;...
BioCentury | Oct 6, 2014
Clinical News

THR-184: Phase II ongoing

...patients. THR-184 has Fast Track designation in the U.S. to prevent cardiac surgery associated AKI. Thrasos Therapeutics Inc....
BioCentury | Jun 23, 2014
Company News

Thrasos Therapeutics Inc management update

Thrasos Therapeutics Inc ., Montreal, Quebec Business: Renal, Cancer, Musculoskeletal Hired: Donald Notman as SVP and CFO, formerly a managing director and head of private capital markets at Leerink Partners WIR Staff cancer Musculoskeletal Renal...
BioCentury | Oct 29, 2012
Financial News

Thrasos Therapeutics completes venture financing

Thrasos Therapeutics Inc. , Montreal, Quebec Business: Renal, Cancer, Musculoskeletal Date completed: 10/25/12 Type: Venture financing Raised: $35 million Investors: SR One; Advanced Technology Ventures; Fonds de solidarite FTQ; Lumira Capital; MP Healthcare Venture; Pappas Ventures;...
BioCentury | Oct 26, 2012
Financial News

Thrasos raises $35M

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $35 million in a series C round led by new investor SR One. New investors Advanced Technology Ventures; Fonds de solidarite; Lumira Capital; MP Healthcare; and Pappas Ventures joined...
BioCentury | Feb 16, 2012
Distillery Therapeutics

Indication: Renal disease

...the cyclic peptide-based ALK3 agonist THR-123 prevented progression or reversed fibrosis compared with no treatment. Thrasos Therapeutics Inc....
Items per page:
1 - 10 of 12
BioCentury | Oct 11, 2017
Company News

Management tracks: Aerpio, Scancell, TCR2

...company Azitra Inc. (Farmington, Conn.) named Richard Andrews president and CEO. He was CEO of Thrasos Therapeutics Inc....
BioCentury | Mar 21, 2016
Clinical News

THR-184: Phase II data

...placebo or 1 of 4 dose levels of THR-184 administered prior to and after surgery. Thrasos Therapeutics Inc....
BioCentury | Jul 27, 2015
Clinical News

THR-184: Completed Phase II enrollment

...2 lower dose arms (see BioCentury, Oct. 6, 2014). Data are expected by January 2016. Thrasos Therapeutics Inc....
BioCentury | Apr 6, 2015
Financial News

Thrasos Therapeutics completes venture financing

Thrasos Therapeutics Inc. , Montreal, Quebec Business: Renal, Cancer, Musculoskeletal Date completed: 2015-03-31 Type: Venture financing Raised: $21 million Investors: BDC Capital; SROne; Fonds de solidarite FTQ; Lumira Capital; Advanced Technology Ventures; MP Healthcare Venture Management...
BioCentury | Apr 1, 2015
Financial News

Thrasos raises $21M in series D

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $21 million in a series D round led by new investor BDC Capital and existing investor SR One. Current investors Advanced Technology Ventures; Fonds de solidarite FTQ; Lumira Capital;...
BioCentury | Oct 6, 2014
Clinical News

THR-184: Phase II ongoing

...patients. THR-184 has Fast Track designation in the U.S. to prevent cardiac surgery associated AKI. Thrasos Therapeutics Inc....
BioCentury | Jun 23, 2014
Company News

Thrasos Therapeutics Inc management update

Thrasos Therapeutics Inc ., Montreal, Quebec Business: Renal, Cancer, Musculoskeletal Hired: Donald Notman as SVP and CFO, formerly a managing director and head of private capital markets at Leerink Partners WIR Staff cancer Musculoskeletal Renal...
BioCentury | Oct 29, 2012
Financial News

Thrasos Therapeutics completes venture financing

Thrasos Therapeutics Inc. , Montreal, Quebec Business: Renal, Cancer, Musculoskeletal Date completed: 10/25/12 Type: Venture financing Raised: $35 million Investors: SR One; Advanced Technology Ventures; Fonds de solidarite FTQ; Lumira Capital; MP Healthcare Venture; Pappas Ventures;...
BioCentury | Oct 26, 2012
Financial News

Thrasos raises $35M

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $35 million in a series C round led by new investor SR One. New investors Advanced Technology Ventures; Fonds de solidarite; Lumira Capital; MP Healthcare; and Pappas Ventures joined...
BioCentury | Feb 16, 2012
Distillery Therapeutics

Indication: Renal disease

...the cyclic peptide-based ALK3 agonist THR-123 prevented progression or reversed fibrosis compared with no treatment. Thrasos Therapeutics Inc....
Items per page:
1 - 10 of 12